EIF5A2 is a novel chemoresistance gene in breast cancer

Breast Cancer

Volumn 22, Issue 6, 2015, Pages 602-607

  Liu, Yu ^a   Du, Feiya ^a   Chen, Wei ^a   Yao, Minya ^a   Lv, Kezhen ^a   Fu, Peifen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Breast cancer; Chemoresistance; Doxorubicin; eIF 5A2

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; DOXORUBICIN; SMALL INTERFERING RNA; ANTINEOPLASTIC ANTIBIOTIC; INITIATION FACTOR; INITIATION FACTOR 5A; RNA BINDING PROTEIN;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL MEDIATED CYTOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; ONCOGENE; ONCOGENE EIF5A2; PRIORITY JOURNAL; WESTERN BLOTTING; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MCF-7 CELLS; PEPTIDE INITIATION FACTORS; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS;

EID: 84945444221     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-014-0526-2     Document Type: Article

References (38)

1. Howlader N, Noone AM, Krapcho M: SEER CancerStatistics Review, 1975–2008, National Cancer Institute.Bethesda, MD, based on November 2010 SEER data submission, posted to the SEER website. http://seer.cancer.gov/csr/1975_2008/ (2011).
2. Christensen LA, Finch RA, Booker AJ, Vasquez KM. Targeting oncogenes to improve breast cancer chemotherapy. Cancer Rese. 2006;66:4089–94.
3. Antoon JW, White MD, Slaughter EM, Driver JL, Khalili HS, Elliott S, et al. Targeting NF κB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther. 2011;11:678–89.
4. He QJ, Zeng WF, Sham JS, Xie D, Yang XW, Lin HL, et al. Recurrent genetic alterations in 26 colorectal carcinomas and 21 adenomas from Chinese patients. Cancer Genet Cytogenet. 2003;144:112–8.
5. Ried T, Knutzen R, Steinbeck R, Blegen H, Schröck E, Heselmeyer K, du Manoir S, Auer G. Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors. Genes Chromosome Cancer. 1996;15:234–45.
6. Sham JS, Tang TC, Fang Y, Sun L, Qin LX, Wu QL, Xie D, Guan XY. Recurrent chromosome alterations in primary ovarian carcinoma in Chinese women. Cancer Genet Cytogenet. 2002;133:39–44.
7. Kettunen E, El-Rifai W, Björkqvist AM, Wolff H, Karjalainen A, Anttila S, et al. A broad amplification pattern at 3q in squamous cell lung cancer e a fluorescence in situ hybridization study. Cancer Genet Cytogenet. 2000;117:66–70.
8. Pack SD, Karkera JD, Zhuang Z, Pak ED, Balan KV, Hwu P, et al. Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent patter n of chromosomal alterations. Genes Chromosome Cancer. 1999;25:160–8.
9. Guan XY, Fu SB, Xia JC, Fang Y, Sham JS, Du BD, et al. Recurrent chromosome changes in 62 primary gastric carcinomas detected by comparative genomic hybridization. Cancer Genet Cytogenet. 2000;123:27–34.
10. Rao PH, Arias-Pulido H, Lu XY, Harris CP, Vargas H, Zhang FF, et al. Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer. 2004;4:5.
11. Sattler HP, Rohde V, Bonkhoff H, Zwergel T, Wullich B. Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer. Prostate. 1999;39:79–86.
12. Horlings HM, Lai C, Nuyten DS, Halfwerk H, Kristel P, van Beers E, et al. Gene expression signatures in breast cancer patients integration of DNA copy number alterations and prognostic. Clin Cancer Res. 2010;16:651–63.
13. Guan XY, Sham JS, Tang TC, Fang Y, Huo KK, Yang JM. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res. 2001;61:3806–9.
14. Guan XY, Fung JM, Ma NF, Lau SH, Tai LS, Xie D, et al. Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Res. 2004;64:4197–200.
15. Lee NP, Tsang FH, Shek FH, Mao M, Dai H, Zhang C, et al. Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma. Int J Cancer. 2010;127:968–76.
16. Yang GF, Xie D, Liu JH, Luo JH, Li LJ, Hua WF, et al. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new in dependent predictor of outcome in patients with ovarian carcinoma. Gynecol Oncol. 2009;112:314–8.
17. Luo JH, Hua WF, Rao HL, Liao YJ, Kung HF, Zeng YX, et al. Overexpression of EIF-5A2 predict s tumor recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder. Cancer Sci. 2009;100:896–902.
18. He LR, Zhao HY, Li BK, Liu YH, Liu MZ, Guan XY, et al. Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non–small cell lung cancer patients. Int J Cancer. 2011;129:143–50.
19. Tang DJ, Dong SS, Ma NF, Xie D, Chen L, Fu L, et al. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology. 2010;51:1255–63.
20. Zhu W, Cai MY, Tong ZT, Dong SS, Mai SJ, Liao YJ, et al. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial mesenchymal transition. Gut. 2012;61:562–75.
21. Zeng C, Liu Y, Hu YZ, Zhao QB, Chi SM. Inhibitory effect of Rab23 on growth and proliferation of breast cancer cells. Prog Mod Biomed. 2009;20:3811–5.
22. Bartucci M, Morelli C, Mauro L, Andò S, Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7and ER-negative MDA-MB-231 breast cancer cells. Cancer Res. 2001;61:6747–54.
23. Rowe DL, Ozbay T, O’Regan RM, Nahta R. Modulation of the BRCA1 protein and induction of apoptosis in triple negative breast cancer cell lines by the polyphenolic compound curcumin. Breast Cancer. 2009;3:61–75.
24. Cooper HL, Park MH, Folk JE. Posttranslational formation of hypusine in a single major protein occurs generally in growing cells and is associated with activation of lymphocyte growth. Cell. 1982;29:791–7.
25. Schnier J, Schwelberger HG, Smit-McBride Z, Kang HA, Hershey JW. Translation initiation factor 5A and its hypusine modification are essential for cell viability in the yeast Saccharomyces cerevisiae. Mol Cell Biol. 1991;11:3105–14.
26. Wohl T, Klier H, Ammer H, Lottspeich F, Magdolen V. The HYP2 gene of Saccharomyces cerevisiae is essential for aerobic growth: characterization of different isoforms of the hypusine-containing protein Hyp2p and analysis of gene disruption mutants. Mol Gen Genet. 1993;241:305–11.
27. Benne R, Hershey JW. The mechanism of action of protein synthesis initiation factors from rabbit reticulocytes. J Biol Chem. 1978;253:3078–87.
28. Kang HA, Hershey JW. Effect of initiation factor eIF-5A depletion on protein synthesis and proliferation of Saccharomyces cerevisiae. J Biol Chem. 1994;269:3934–40.
29. Xu A, Jao DL, Chen KY. Identification of mRNA that binds to eukaryotic initiation factor 5A by affinity co-purification and differential display. Biochem J. 2004;384:585–90.
30. Zanelli CF, Valentini SR. Pkc1 acts throug h Zds1 and Gic1 to sup-press growth and cell polarity defects of a yeast eIF5A mutant. Genetics. 2005;171:1571–81.
31. Smit-McBride Z, Dever TE, Hershey JW, Merrick WC. Sequence determination and cDNA cloning of eukar yotic initiation factor 4D, the hypusine-containing protein. J Biol Chem. 1989;264:1578–83.
32. Koettnitz K, Wohl T, Kappel B, Lottspeich F, Hauber J, Bevec D. Identification of a new member of the human eIF-5A gene family. Gene. 1995;159:283–4.
33. Clement PM, Henderson CA, Jenkins ZA, Smit-McBride Z, Wolff EC, Hershey JW, et al. Identification and characterization of eukaryotic initiation factor 5A-2. Eur J Biochem. 2003;270:4254–63.
34. Jenkins ZA, Haag PG, Johansson HE. Human eIF5A2 on chromo-some 3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic translation initiation factor 5A with tissue-specific expression. Genomics. 2001;71:101–9.
35. Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun. 2012;417:679–85.
36. Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Nerini IF, et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer. 2013;49:520–30.
37. Güngör C, Zander H, Effenberger KE, Vashist YK, Kalinina T, Izbicki JR, et al. Notch signaling activated by replication stress-induced expression of midline drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res. 2011;71:5009–19.
38. Chen X, Lingala S, Khoobyari S, Nolta J, Zern MA, Wu J. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol. 2011;55:838–45.